Inflammation and biologic therapy in patients with rheumatoid arthritis achieving versus not achieving ACR/EULAR Boolean remission in a treat-to-target study
Objective To investigate limiting factors of American College of Rheumatology (ACR)/EULAR Boolean remission in rheumatoid arthritis (RA), and compare patients who fulfil the criteria to patients who only partly fulfil the criteria, with respect to imaging inflammation and biologic disease modifying...
Published in: | RMD Open |
---|---|
Main Authors: | , , , , , , , , |
Other Authors: | , , , , , , , , |
Format: | Article in Journal/Newspaper |
Language: | English |
Published: |
BMJ
2022
|
Subjects: | |
Online Access: | http://dx.doi.org/10.1136/rmdopen-2021-002013 https://syndication.highwire.org/content/doi/10.1136/rmdopen-2021-002013 |
id |
crjcrbmj:10.1136/rmdopen-2021-002013 |
---|---|
record_format |
openpolar |
spelling |
crjcrbmj:10.1136/rmdopen-2021-002013 2024-04-28T08:11:25+00:00 Inflammation and biologic therapy in patients with rheumatoid arthritis achieving versus not achieving ACR/EULAR Boolean remission in a treat-to-target study Paulshus Sundlisæter, Nina Sundin, Ulf Aga, Anna-Birgitte Sexton, Joseph Hammer, Hilde Berner Uhlig, Till Kvien, Tore K Haavardsholm, Espen A Lillegraven, Siri Merck Sharp and Dohme Norske Kvinners Sanitetsforening Roche Norsk Revmatikerforbund UCB AbbVie Pfizer Norges Forskningsråd Helse Sør-Øst RHF 2022 http://dx.doi.org/10.1136/rmdopen-2021-002013 https://syndication.highwire.org/content/doi/10.1136/rmdopen-2021-002013 en eng BMJ http://creativecommons.org/licenses/by-nc/4.0/ RMD Open volume 8, issue 1, page e002013 ISSN 2056-5933 Immunology Immunology and Allergy Rheumatology journal-article 2022 crjcrbmj https://doi.org/10.1136/rmdopen-2021-002013 2024-04-02T07:56:03Z Objective To investigate limiting factors of American College of Rheumatology (ACR)/EULAR Boolean remission in rheumatoid arthritis (RA), and compare patients who fulfil the criteria to patients who only partly fulfil the criteria, with respect to imaging inflammation and biologic disease modifying anti-rheumatic drug (DMARD) usage. Methods Patients with DMARD-naïve RA were treated according to current recommendations in the the ARCTIC trial (Aiming for Remission in rheumatoid arthritis: a randomised trial examining the benefit of ultrasound in a Clinical TIght Control regimen). Limiting factors of reaching ACR/EULAR Boolean remission at 2 years were assessed. Imaging inflammation (ultrasound and MRI) in patients in remission was compared with patients failing to fulfil different components of the criteria. The OR of biologic therapy was calculated using logistic regression. Results Of 203 patients, 112 (55%) reached ACR/EULAR Boolean remission; 49 (24%) fulfilled three of four criteria. The main limiting factors were patient global assessment (PGA) (59%) and tender joints (22%). Imaging inflammation was not significantly different for patients in remission and patients not fulfilling the criteria due to elevated PGA and/or tender joints, but higher odds of using biologics (OR 3.63, 95% CI 1.73 to 7.61) were observed. Conclusions PGA and tender joints were the factors most often limiting achievement of ACR/EULAR Boolean remission. The level of imaging inflammation was not elevated in these patients compared with patients in remission, but the odds of using biologic DMARDs were higher. Article in Journal/Newspaper Arctic The BMJ RMD Open 8 1 e002013 |
institution |
Open Polar |
collection |
The BMJ |
op_collection_id |
crjcrbmj |
language |
English |
topic |
Immunology Immunology and Allergy Rheumatology |
spellingShingle |
Immunology Immunology and Allergy Rheumatology Paulshus Sundlisæter, Nina Sundin, Ulf Aga, Anna-Birgitte Sexton, Joseph Hammer, Hilde Berner Uhlig, Till Kvien, Tore K Haavardsholm, Espen A Lillegraven, Siri Inflammation and biologic therapy in patients with rheumatoid arthritis achieving versus not achieving ACR/EULAR Boolean remission in a treat-to-target study |
topic_facet |
Immunology Immunology and Allergy Rheumatology |
description |
Objective To investigate limiting factors of American College of Rheumatology (ACR)/EULAR Boolean remission in rheumatoid arthritis (RA), and compare patients who fulfil the criteria to patients who only partly fulfil the criteria, with respect to imaging inflammation and biologic disease modifying anti-rheumatic drug (DMARD) usage. Methods Patients with DMARD-naïve RA were treated according to current recommendations in the the ARCTIC trial (Aiming for Remission in rheumatoid arthritis: a randomised trial examining the benefit of ultrasound in a Clinical TIght Control regimen). Limiting factors of reaching ACR/EULAR Boolean remission at 2 years were assessed. Imaging inflammation (ultrasound and MRI) in patients in remission was compared with patients failing to fulfil different components of the criteria. The OR of biologic therapy was calculated using logistic regression. Results Of 203 patients, 112 (55%) reached ACR/EULAR Boolean remission; 49 (24%) fulfilled three of four criteria. The main limiting factors were patient global assessment (PGA) (59%) and tender joints (22%). Imaging inflammation was not significantly different for patients in remission and patients not fulfilling the criteria due to elevated PGA and/or tender joints, but higher odds of using biologics (OR 3.63, 95% CI 1.73 to 7.61) were observed. Conclusions PGA and tender joints were the factors most often limiting achievement of ACR/EULAR Boolean remission. The level of imaging inflammation was not elevated in these patients compared with patients in remission, but the odds of using biologic DMARDs were higher. |
author2 |
Merck Sharp and Dohme Norske Kvinners Sanitetsforening Roche Norsk Revmatikerforbund UCB AbbVie Pfizer Norges Forskningsråd Helse Sør-Øst RHF |
format |
Article in Journal/Newspaper |
author |
Paulshus Sundlisæter, Nina Sundin, Ulf Aga, Anna-Birgitte Sexton, Joseph Hammer, Hilde Berner Uhlig, Till Kvien, Tore K Haavardsholm, Espen A Lillegraven, Siri |
author_facet |
Paulshus Sundlisæter, Nina Sundin, Ulf Aga, Anna-Birgitte Sexton, Joseph Hammer, Hilde Berner Uhlig, Till Kvien, Tore K Haavardsholm, Espen A Lillegraven, Siri |
author_sort |
Paulshus Sundlisæter, Nina |
title |
Inflammation and biologic therapy in patients with rheumatoid arthritis achieving versus not achieving ACR/EULAR Boolean remission in a treat-to-target study |
title_short |
Inflammation and biologic therapy in patients with rheumatoid arthritis achieving versus not achieving ACR/EULAR Boolean remission in a treat-to-target study |
title_full |
Inflammation and biologic therapy in patients with rheumatoid arthritis achieving versus not achieving ACR/EULAR Boolean remission in a treat-to-target study |
title_fullStr |
Inflammation and biologic therapy in patients with rheumatoid arthritis achieving versus not achieving ACR/EULAR Boolean remission in a treat-to-target study |
title_full_unstemmed |
Inflammation and biologic therapy in patients with rheumatoid arthritis achieving versus not achieving ACR/EULAR Boolean remission in a treat-to-target study |
title_sort |
inflammation and biologic therapy in patients with rheumatoid arthritis achieving versus not achieving acr/eular boolean remission in a treat-to-target study |
publisher |
BMJ |
publishDate |
2022 |
url |
http://dx.doi.org/10.1136/rmdopen-2021-002013 https://syndication.highwire.org/content/doi/10.1136/rmdopen-2021-002013 |
genre |
Arctic |
genre_facet |
Arctic |
op_source |
RMD Open volume 8, issue 1, page e002013 ISSN 2056-5933 |
op_rights |
http://creativecommons.org/licenses/by-nc/4.0/ |
op_doi |
https://doi.org/10.1136/rmdopen-2021-002013 |
container_title |
RMD Open |
container_volume |
8 |
container_issue |
1 |
container_start_page |
e002013 |
_version_ |
1797578846916050944 |